Navigation Links
Nuvelo Reports Second Quarter 2008 Financial Results
Date:7/23/2008

target="_new">http://www.nuvelo.com.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy- induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the potential benefits that patients may experience from the use of our clinical stage compounds, and our anticipated use of cash, which statements are hereby identified as "forward- looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... and adults, HIGHLANDS RANCH, Colo., Dec. 19 ... treatment services to,include a detox program. The new program ... and the hospital has added several new physicians that,specialize ... and,mental illness)., Teen suicide rates nationally are on ...
... Calif., Dec. 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... MD, FACC to its Board of Directors. Dr. Barron ... at Genentech,where he leads the Development organization, which is ... joined Genentech in 1996 as a clinical scientist and ...
... CLEVELAND, Dec. 19 Cleveland Medical Devices ... $1.5 million in NIH SBIR,Phase II Continuation ... and Stroke (NINDS). The grant will fund ... quantitative motor assessment system,for evaluating Parkinson,s disease ...
Cached Biology Technology:Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinson's Disease Motor Symptoms 2
(Date:8/21/2014)... the Fram Strait is a key region in the global ... Greenland and Svalbard warm Atlantic water flows to the north ... Arctic water masses and sea ice push their way out ... of the Atlantic water cools here on its way to ... the water caused in this manner drives the global band ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
(Date:8/21/2014)... Acute pancreatitis involves the pancreas digesting itself resulting in ... in the UK around 20,000 patients are diagnosed with ... immediate cure and treatment is restricted to intravenous fluid ... the Faculty of Life Sciences, who led the research, ... reflux from gall stones and excessive alcohol intake combined ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... in humans in forests between Gabon and the Republic ... animal carcasses, according to a study by the Wildlife ... the February edition of the journal Emerging Infectious Diseases, ... Ebola between 2001 and 2003 produced positive results, and ...
... by human activity and the extinction of species around ... warns a Canadian zoologist. This ecological damage also endangers ... , Dr. Daniel (Dan) Brooks, a parasitologist at the ... is linked to the emergence of new human and ...
Cached Biology News:Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Study Links Ebola Outbreaks To Animal Carcasses 2Ecological destruction fuels emerging diseases 2
... exciting new chapter to a ... Agilents 7890A GC gives you ... your lab to the next ... performance, including advanced separation capabilities, ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... CaspaTag™ Pan-Caspase In Situ Assay Kit is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
Biology Products: